Noxxon Pharma AG said that it has raised €33 million in a Series D round of financing to support the ongoing clinical and preclinical development of its mirror-image oligonucleotides known as Spiegelmers. The round was led by NGN Capital. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
